



A33474-PCT-USA-A - 068528.0103

16/4

1651

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Higuchi et al. Examiner : Not Yet Assigned  
Serial No. : 10/086,913 Group Art Unit: 1614  
Filed : March 1, 2002  
For : PREVENTION AND TREATMENT OF MYCOPLASMA-ASSOCIATED DISEASES  
Customer No. : 21003

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12/18/03  
Date of Deposit

Lisa B. Kole  
Attorney Name  
Lisa B. Kole  
Signature

35,225  
PTO Reg. No.  
12/18/03  
Date of Signature

Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the documents listed below in reverse chronological order and on the accompanying PTO 1449 be considered by the Examiner and made of record in the above-referenced application. Copies of the documents listed are enclosed.

Several of the listed documents have been cited on the International Search Report for International Patent Application No. PCT/BR01/00083, to which the

present application claims priority. A copy of the International Search Report is also enclosed, which indicates the possible relevance of each document cited therein.

1. Umezawa et al., "Enzyme-linked immunosorbent assay with *Trypanosoma cruzi* excreted-secreted antigens (TESA-ELISA) for serodiagnosis of acute and chronic Chagas' disease," Diagn. Microbiol. Infect. Dis. 39:169-176, 2001 (USA).
2. Higuchi et al., "Great amount of *C. pneumoniae* in ruptured plaque vessel segments at autopsy. A comparative study of stable plaques," Ara. Bras. Cardiol. 74:149-151(2000).
3. Higuchi et al., "Detection of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in ruptured atherosclerotic plaques," Braz. J. Med. Biol. Res. 33:1023-1026 (2000).
4. Horne et al., "IgA sero-positivity to *Mycoplasma pneumoniae* predicts the diagnosis of coronary artery disease," J. Am. Coll. Cardiol. 35:321 (abstract) (2000).
5. Laroy et al., "Cloning of *Trypanosoma cruzi* trans-Sialidase and Expression in *Pichia pastoris*," Protein Expr. Purif. 20:389-393 (2000).
6. Maraha et al., "Is *Mycoplasma pneumoniae* associated with vascular disease," J. Clin. Microbiol. 38:935-936 (February 2000).
7. Sambiase et al., "CMV and transplant-related coronary atherosclerosis: an immunohistochemical, *in situ* hybridization and polymerase chain reaction *in situ* study," Modern Pathology 13:173-179 (2000).
8. Buscaglia et al., "Tandem amino acid repeats from *Trypanosoma cruzi* shed antigens increase the half-life of proteins in blood", Blood, 93:2025-2032, (1999).

9. Cole, "Mycoplasma-induced arthritis in animals: relevance to understanding the etiologies of the human rheumatic diseases," Rev. Rhum. Engl. Ed. 66 (1 Suppl):45S-49S (1999).

10. Berbec et al., "Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia," Eur J Gynaecol On col 20(5-6): 389-392 (1999).

11. Feng Shaw-Huey, et al., "Mycoplasma infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells," Mol Cel Biol 19(12): 7995-8002 (1999).

12. Nicolson et al., "Mycoplasma infections in chronic illnesses," (<http://www.gulfwarvets.com/article24.htm>), also published in Medical Sentinel, 4:172-175,191 (1999).

13. Ros-Bullon , et al., "Serum sialic acid in malignant melanoma patients: na ROC curve analysis," Anticancer Res 19(4C): 3619-3622 (1999).

14. Buscaglia et al., "The repetitive domain of *Trypanosome cruzi* trans-sialidase enhances the immune response against the catalytic domain," J. Infect. Dis. 177(2):431-436 (1998).

15. Fu et al., "Middle cerebral artery occlusion after recent *Mycoplasma pneumoniae* infection," J. Neurol. Sci. 157:113-115 (1998).

16. Neyrolles et al., "Identification of two glycosylated components of *Mycoplasma penetrans*:a surface-exposed capsular polysaccharide and a glycolipid fraction," Microbiology, 144:1247-1255 (1998).

17. Razin et al., "Molecular biology and pathogenicity of mycoplasmas," Microbiol. Mol. Biol. Rev. 62(4):1094-1156 (1998).
18. Taylor-Robinson and Thomas, "*Chlamydia pneumoniae* in arteries: the facts, their interpretation, and future studies," J. Clin. Pathol. 51:793-797 (1998).
19. Agusti et al., "The trans-sialidase of *Trypanosoma cruzi* is anchored by two different lipids," Glycobiology 7(6):731-735 (1997).
20. Cole, "Mycoplasma interactions with the immune system: implications for disease pathology," (1997),  
<http://www.compkarori.com/arthritis/pil6002.htm>.
21. Danesch et al., "Chronic infections and coronary artery disease: is there a link?," Lancet 350:430-436 (1997).
22. Farraj et al., "Mycoplasma-associated pericarditis, case report," Mayo Clin. Proc. 72:33-36 (1997).
23. Gurfinkel et al., "IgG antibodies to chlamydial and mycoplasma infection plus C-reactive protein related to poor outcome in unstable angina," Arch. Inst. Cardiol. Mex. 67:462-468 (1997).
24. Ribeirão et al., "Temperature differences for trans-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of *Trypanosoma cruzi* trans-sialidase," Glycobiology 7:1237-1246 (1997).
25. Perez et al., "Leukocytoclastic vasculitis and polyarthritis associated with *Mycoplasma pneumoniae* infection," Clin. Infect. Dis. 25:154-155 (1997).
26. *Trypanosoma cruzi* trans-sialidase, Accession No. BAA09334, GI:840708,1060 aa, Smith et al. (1996).

27. *Trypanosoma cruzi* trans-sialidase, Accession No. BAA09333, GI:84706, 964 aa, Smith et al. (1996).

28. Buschiazzo et al., "Medium scale production and purification to homogeneity of a recombinant trans-sialidase from *Trypanosoma cruzi*," Cell Mol. Biol. 42:703-710 (1996).

29. Cremona et al., "Effect of primary structure modifications in *Trypanosoma cruzi* neuramindase trans-sialidase activities," Cell. Mol. Biol. 42:697-702 (1996).

30. Ong et al., "Detection and widespread distribution of *Chlamydia pneumoniae* in the vascular system and its possible implications," J. Clin. Pathol. 49:102-106 (1996).

31. Umezawa et al., "Immunoblot assay using excreted/secreted antigens of *Trypanosoma cruzi* in serodiagnosis of congenital, acute and chronic Chagas' disease," J. Clin. Microbiol. 34: 2143-2147, (1996).

32. *Trypanosoma cruzi* TCTS-154 gene for trans-sialidase, Accession No D50684, GI:840705, 2895 bp, Uemura et al. (1995).

33. *Trypanosoma cruzi* TCTS-121 gene for trans-sialidase, Accession No D50685, GI:840707, 3183 bp, Uemura et al. (1995).

34. Cremona et al., "A single tyrosine differentiates active and inactive *Trypanosome cruzi* trans-sialidase," Gene 160:123-128 (1995).

35. Blanchard et al., "AIDS-associated mycoplasmas," Annu. Rev. Microbiol. 48:687-712 (1994).

36. Campetella et al., "A recombinant *Trypanosoma cruzi* trans-sialidase lacking the amino acid repeats retains the enzymatic activity," Mol. Biochem. Parasitol. 64:337-340 (1994).
37. Schenkman et al., "Structural and functional properties of Trypanosome trans-sialidase," Annu. Rev. Microbiol. 48:499-523 (1994).
38. Schenkman et al., "A proteolytic fragment of *Trypanosoma cruzi* trans-sialidase lacking the carboxy-terminal domain is active, monomeric, and generates antibodies that inhibit enzymatic activity" J. Biol. Chem. 269:7970-7975 (1994).
39. *Trypanosoma cruzi* trans-sialidase homologue, Accession No. AAC98544, GI:624626, 736 aa, Briones et al. , (1993).
40. Scudder et al., "Enzymatic characterization of beta-D-galactoside alpha 2,3-trans-sialidase from *Trypanosome cruzi*," J. Biol. Chem. 268(13):9886-9891 (1993).
41. *Trypanosoma cruzi* trans-sialidase-neuraminidase, Accession No. S28409, GI:323067, 200 aa, Uemura et al., (1992).
42. Simecka et al., "Mycoplasmas Diseases of Animals," in Maniloff et al. Eds., Mycoplasmas. Molecular Biology and Pathogenesis, American Society for Microbiology, pp. 391-415 (Washington, 1992).
43. Parodi et al., "Identification of the gene(s) coding for the trans-sialidase of *Trypanosome cruzi*" EMBO J. 11:1705-1710 (1992).
44. Schenkman et al., "*Trypanosoma cruzi* trans-sialidase and neuraminidase activities can be mediated by the same enzymes," J Exp Med 175(2):567-575 (1992).
45. Uemura et al., "Only some members of a gene family in *Trypanosome cruzi* encode proteins that express both trans-sialidase and neuraminidase activities," EMBO J. 11:3837-3844 (1992).

46. Vandekerckhove et al., "Substrate specificity of the *Trypanosoma cruzi* trans-sialidase," Glycobiology 2(6):541-548, (1992).
47. Pereira et al., "The *Trypanosoma cruzi* neuraminidase contains sequences similar to bacterial neuraminidases, YWTD repeats of the low density lipoprotein receptor, and Type III modules of fibronectin," J. Ex. Med. 174:179-191 (1991).
48. Pollevick et al., "The complete sequence of a shed acute-phase antigen of *Trpanosoma cruzi*," Mol. Biochem. Parasitol. 47:247-250 (1991).
49. Schenkman et al., "Attachment of *Trypanosoma cruzi* trypomastigotes to receptors at restricted cell surface domains," Exp. Parasitol. 72:76-86 (1991).
50. Roberts et al., "Sialic Acid-dependent Adhesion of *Mycoplasma pneumoniae* to Purified Glycoproteins," Journal of Biological Chemistry, 264:9289-9293 (1989).
51. Chen et al., "Carditis associated with *Mycoplasma pneumoniae* infection," Am. J. Dis. Child. 140:471-472 (1986).
52. Pereira, "A developmentally regulated neuraminidase activity in *Trypanosoma cruzi*," Science 219:1444-1446 (1983).
53. Kahane, "Purification of attachment moiety: a review," Yale J. Biol. Med. 53:665-669 (1983).
54. Baseman et al., "Sialic acid residues mediate *Mycoplasma pneumoniae* attachment to human and sheep erythrocytes," Infect. Immun. 38(1):389-391 (1982).
55. Bredt et al., "Adherence of mycoplasmas: phenomena and possible role in the pathogenesis of disease," Infection 10(3):199-201 (1982).

56. Chandler et al., "Mycoplasma pneumoniae attachment: competitive inhibition by mycoplasmal binding component and by sialic acid-containing glycoconjugates," Infect. Immun. 38(2):598-603 (1982).

57. Krause et al., "Identification of *Mycoplasma pneumoniae* proteins associated with hemadsorption and virulence," Infect. Immun. 35:809-817 (1982).

58. Hansen et al., "Characterization of hemadsorption-negative mutants of *Mycoplasma pneumoniae*," Infect. Immun. 32:127-136 (1981).

59. Kahane et al., "Attachment of mycoplasmas to erythrocytes: a model to study mycoplasma attachment to the epithelium of the host respiratory tract," Isr. J. Med. Sci. 17:589-592 (1981).

60. Taylor-Robinson et al., "Mycoplasmal adherence with particular reference to the pathogenicity of *Mycoplasma pulmonis*," Isr. J. Med. Sci. 17:599-603 (1981).

61. Glasgow and Hill, "Interactions of *Mycoplasma gallisepticum* with sialyl glycoproteins," Infect. Immun. 30:353-361 (1980).

62. Pereira et al., "Lectin receptors as markers for *Trypanosoma cruzi*. Development stages and a study of the interaction of wheat germ agglutinin with sialic acid residues on epimastigotes cells," J. Exp. Med., 152:1375-1392 (1980).

63. Gabridge and Taylor-Robinson, "Interaction of *Mycoplasma pneumoniae* with human lung fibroblasts: role of receptor sites," Infect. Immun. 25:455-459 (1979).

64. Clyde et al., "Tropism for *Mycoplasma gallisepticum* for arterial walls," Proc. Natl. Acad. Sci. U.S.A. 70: 1545-1549 (1973).


65. Collier and Clyde, "Relationships between *M. pneumoniae* and human respiratory epithelium," Infect. Immun. 3:694-701 (1971).

Identification of the listed documents is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as "prior art" against the subject application. If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

There should be no fee required for this submission. However, if any fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this paper is enclosed.

Respectfully submitted,  
BAKER BOTTS L.L.P.



Lisa B. Kole  
PTO Reg. No. 35,225

30 Rockefeller Plaza  
44th Floor  
New York, NY 10012-4498


Attorneys for Applicants  
(212) 408-2568

Identification of the listed documents is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as "prior art" against the subject application. If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

There should be no fee required for this submission. However, if any fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this paper is enclosed.

Respectfully submitted,  
BAKER BOTTS L.L.P.



Lisa B. Kole  
PTO Reg. No. 35,225

30 Rockefeller Plaza  
44th Floor  
New York, NY 10012-4498

Attorneys for Applicants  
(212) 408-2568

Atty. Docket No.  
A33474-PCT-USA-A  
068528.0103

Serial No.  
10/086,913

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

DEC 22 2003



Applicant  
Higuchi et al.

Filing Date  
March 1, 2002

Group

U.S. PATENT DOCUMENTS

*Ex am.	Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENT

		Document No.	Date	Country	Class	SubClass	Translation Yes No

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

1		Umezawa et al., "Enzyme-linked immunosorbent assay with <i>Trypanosoma cruzi</i> excreted-secreted antigens (TESA-ELISA) for serodiagnosis of acute and chronic Chagas' disease," <i>Diagn. Microbiol. Infect. Dis.</i> 39:169-176, 2001 (USA).
2		Higuchi et al., "Great amount of <i>C. pneumoniae</i> in ruptured plaque vessel segments at autopsy. A comparative study of stable plaques," <i>Ara. Bras. Cardiol.</i> 74:149-151(2000).
3		Higuchi et al., "Detection of <i>Mycoplasma pneumoniae</i> and <i>Chlamydia pneumoniae</i> in ruptured atherosclerotic plaques," <i>Braz. J. Med. Biol. Res.</i> 33:1023-1026 (2000).
4		Horne et al., "IgA sero-positivity to <i>Mycoplasma pneumoniae</i> predicts the diagnosis of coronary artery disease," <i>J. Am. Coll. Cardiol.</i> 35:321 (abstract) (2000).

NY02:450221.1

1

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.  
A33474-PCT-USA-A  
068528.0103

Serial No.  
10/086,913

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

DEC 22 2003

Applicant  
Higuchi et al.

Filing Date  
March 1, 2002

Group

5	Laroy et al., "Cloning of <i>Trypanosoma cruzi</i> trans-Sialidase and Expression in <i>Pichia pastoris</i> ," <u>Protein Expr. Purif.</u> 20:389-393 (2000).
6	Maraha et al., "Is <i>Mycoplasma pneumoniae</i> associated with vascular disease," <u>J. Clin. Microbiol.</u> 38:935-936 (February 2000).
7	Sambiase et al., "CMV and transplant-related coronary atherosclerosis: an immunohistochemical, <i>in situ</i> hybridization and polymerase chain reaction <i>in situ</i> study," <u>Modern Pathology</u> 13:173-179 (2000).
8	Buscaglia et al., "Tandem amino acid repeats from <i>Trypanosoma cruzi</i> shed antigens increase the half-life of proteins in blood", <u>Blood</u> , 93:2025-2032, (1999).
9	Cole, "Mycoplasma-induced arthritis in animals: relevance to understanding the etiologies of the human rheumatic diseases," <u>Rev. Rhum. Engl. Ed.</u> 66 (1 Suppl):45S-49S (1999).
10	Berbec et al., "Total serum sialic acid concentration as a supporting marker of malignancy in ovarian neoplasia," <u>Eur J Gynaecol Oncol</u> 20(5-6): 389-392 (1999).
11	Feng Shaw-Huey, et al., "Mycoplasma infections prevent apoptosis and induce malignant transformation o interleukin-3-dependent 32D hematopoietic cells," <u>Mol Cel Biol</u> 19(12): 7995-8002 (1999).
12	Nicolson et al., "Mycoplasma infections in chronic illnesses," ( <a href="http://www.gulfwarvets.com/article24.htm">http://www.gulfwarvets.com/article24.htm</a> ) also published in <u>Medical Sentinel</u> , 4 :172-175,191 (1999).
13	Ros-Bullon , et al., "Serum sialic acid in malignant melanoma patients: na ROC curve analysis," <u>Anticancer Res</u> 19(4C): 3619-3622 (1999).
14	Buscaglia et al., "The repetitive domain of <i>Trypanosome cruzi</i> trans-sialidase enhances the immune response against the catalytic domain," <u>J. Infect. Dis.</u> 177(2):431-436 (1998).
15	Fu et al., "Middle cerebral artery occlusion after recent <i>Mycoplasma pneumoniae</i> infection," <u>J. Neurol. Sci.</u> 157:113-115 (1998).

NY02:450221.1


2

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)




Applicant  
Higuchi et al.

Filing Date  
March 1, 2002

Group

16		Neyrolles et al., "Identification of two glycosylated components of <i>Mycoplasma penetrans</i> : a surface-exposed capsular polysaccharide and a glycolipid fraction," <i>Microbiology</i> , 144:1247-1255 (1998).
17		Razin et al., "Molecular biology and pathogenicity of mycoplasmas," <i>Microbiol. Mol. Biol. Rev.</i> 62(4):1094-1156 (1998).
18		Taylor-Robinson and Thomas, " <i>Chlamydia pneumoniae</i> in arteries: the facts, their interpretation, and future studies," <i>J. Clin. Pathol.</i> 51:793-797 (1998).
19		Agusti et al., "The trans-sialidase of <i>Trypanosoma cruzi</i> is anchored by two different lipids," <i>Glycobiology</i> 7(6):731-735 (1997).
20		Cole, "Mycoplasma interactions with the immune system: implications for disease pathology," 1997, <a href="http://www.compkarori.com/arthritis/pil6002.htm">http://www.compkarori.com/arthritis/pil6002.htm</a> .
21		Danesh et al., "Chronic infecFarraj et al., "Mycoplasma-associated pericarditis, case report," <i>Mayo Clin. Proc.</i> 72:33-36 (1997).
22		Farraj et al., "Mycoplasma-associated pericarditis, case report," <i>Mayo Clin. Proc.</i> 72:33-36 (1997).
23		Gurfinkel et al., "IgG antibodies to chlamydial and mycoplasma infection plus C-reactive protein related to poor outcome in unstable angina," <i>Arch. Inst. Cardiol. Mex.</i> 67:462-468 (1997).
24		Ribeirão et al., "Temperature differences for trans-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of <i>Trypanosoma cruzi</i> trans-sialidase," <i>Glycobiology</i> 7:1237-1246 (1997).tions and coronary artery disease: is there a link?," <i>Lancet</i> 350:430-436 (1997).
25		Perez et al., "Leukocytoclastic vasculitis and polyarthritis associated with <i>Mycoplasma pneumoniae</i> infection," <i>Clin. Infect. Dis.</i> 25:154-155 (1997).
26		Trypanosoma cruzi trans-sialidase, Accession No. BAA09334, GI:840708,1060 aa, Smith et al. (1996).

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)



Applicant  
Higuchi et al.

Filing Date  
March 1, 2002

Group

27	Trypanosoma cruzi trans-sialidase, Accession No. BAA09333, GI:84706, 964 aa, Smith et al. (1996).
28	Buschiazzo et al., "Medium scale production and purification to homogeneity of a recombinant trans-sialidase from Trypanosoma cruzi," <u>Cell Mol. Biol.</u> 42:703-710 (1996).
29	Cremona et al., "Effect of primary structure modifications in Trypanosoma cruzi neuramindase trans-sialidase activities," <u>Cell. Mol. Biol.</u> 42:697-702 (1996).
30	Ong et al., "Detection and widespread distribution of <i>Chlamydia pneumoniae</i> in the vascular system and its possible implications," <u>J. Clin. Pathol.</u> 49:102-106 (1996).
31	Umezawa et al., "Immunoblot assay using excreted/secreted antigens of <i>Trypanosoma cruzi</i> in serodiagnosis of congenital, acute and chronic Chagas' disease," <u>J. Clin. Microbiol.</u> 34: 2143-2147, (1996)
32	Trypanosoma cruzi TCTS-154 gene for trans-sialidase, Accession No D50684, GI:840705, 2895 bp, Uemura et al. (1995).
33	Trypanosoma cruzi TCTS-121 gene for trans-sialidase, Accession No D50685, GI:840707, 3183 bp, Uemura et al. (1995).
34	Cremona et al., "A single tyrosine differentiates active and inactive <i>Trypanosome cruzi</i> trans-sialidase," <u>Gene</u> 160:123-128 (1995).
35	Blanchard et al., "AIDS-associated mycoplasmas," <u>Annu. Rev. Microbiol.</u> 48:687-712 (1994).
36	Campetella et al., "A recombinant Trypanosoma cruzi trans-sialidase lacking the amino acid repeats retains the enzymatic activity," <u>Mol. Biochem. Parasitol.</u> 64:337-340 (1994).
37	Schenkman et al., "Structural and functional properties of Trypanosome trans-sialidase," <u>Annu. Rev. Microbiol.</u> 48:499-523 (1994).


Atty. Docket No.  
A33474-PCT-USA-A  
068528.0103

Serial No.  
10/086,913

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)




Applicant  
Higuchi et al.

Filing Date  
March 1, 2002

Group

38	Schenkman et al., "A proteolytic fragment of <i>Trypanosoma cruzi</i> trans-sialidase lacking the carboxy-terminal domain is active, monomeric, and generates antibodies that inhibit enzymatic activity" <i>J. Biol. Chem.</i> 269:7970-7975 (1994).
39	Trypanosoma cruzi trans-sialidase homologue, Accession No. AAC98544, GI:624626, 736 aa, Briones et al., (1993).
40	Scudder et al., "Enzymatic characterization of beta-D-galactoside alpha 2,3-trans-sialidase from <i>Trypanosome cruzi</i> ," <i>J. Biol. Chem.</i> 268(13):9886-9891 (1993).
41	Trypanosoma cruzi trans-sialidase-neuraminidase, Accession No. S28409, GI:323067, 200 aa, Uemura et al., (1992).
42	Simecka et al., "Mycoplasmas Diseases of Animals," in Maniloff et al. Eds., <i>Mycoplasmas. Molecular Biology and Pathogenesis</i> , American Society for Microbiology, pp. 391-415 (Washington, 1992).
43	Parodi et al., "Identification of the gene(s) coding for the trans-sialidase of <i>Trypanosome cruzi</i> " <i>EMBO J.</i> 11:1705-1710 (1992).
44	Schenkman et al., " <i>Trypanosoma cruzi</i> trans-sialidase and neuraminidase activities can be mediated by the same enzymes," <i>J Exp Med</i> 175(2):567-575 (1992).
45	Uemura et al., "Only some members of a gene family in <i>Trypanosome cruzi</i> encode proteins that express both trans-sialidase and neuraminidase activities," <i>EMBO J.</i> 11:3837-3844 (1992).
46	Vandekerckhove et al., "Substrate specificity of the <i>Trypanosoma cruzi</i> trans-sialidase," <i>Glycobiology</i> 2(6):541-548, (1992).
47	Pereira et al., "The <i>Trypanosoma cruzi</i> neuraminidase contains sequences similar to bacterial neuraminidases, YWTD repeats of the low density lipoprotein receptor, and Type III modules of fibronectin," <i>J. Ex. Med.</i> 174:179-191 (1991).
48	Pollevick et al., "The complete sequence of a shed acute-phase antigen of <i>Trpanosoma cruzi</i> ," <i>Mol. Biochem. Parasitol.</i> 47:247-250 (1991).

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)



Applicant  
Higuchi et al.

Filing Date  
March 1, 2002

Group

49	Schenkman et al., "Attachment of <i>Trypanosoma cruzi</i> trypomastigotes to receptors at restricted cell surface domains," <u>Exp. Parasitol.</u> 72:76-86 (1991).
50	Roberts et al., "Sialic Acid-dependent Adhesion of <i>Mycoplasma pneumoniae</i> to Purified Glycoproteins," <u>Journal of Biological Chemistry</u> , 264:9289-9293 (1989).
51	Chen et al., "Carditis associated with <i>Mycoplasma pneumoniae</i> infection," <u>Am. J. Dis. Child.</u> 140:471-472 (1986).
52	Pereira, "A developmentally regulated neuraminidase activity in <i>Trypanosoma cruzi</i> ," <u>Science</u> 219:1444-1446 (1983)
53	Kahane, "Purification of attachment moiety: a review," <u>Yale J. Biol. Med.</u> 53:665-669 (1983).
54	Baseman et al., "Sialic acid residues mediate <i>Mycoplasma pneumoniae</i> attachment to human and sheep erythrocytes," <u>Infect. Immun.</u> 38(1):389-391 (1982).
55	Bredt et al., "Adherence of mycoplasmas: phenomena and possible role in the pathogenesis of disease," <u>Infection</u> 10(3):199-201 (1982).
56	Chandler et al., " <i>Mycoplasma pneumoniae</i> attachment: competitive inhibition by mycoplasmal binding component and by sialic acid-containing glycoconjugates," <u>Infect. Immun.</u> 38(2):598-603 (1982).
57	Krause et al., "Identification of <i>Mycoplasma pneumoniae</i> proteins associated with hemadsorption and virulence," <u>Infect. Immun.</u> 35:809-817 (1982).
58	Hansen et al., "Characterization of hemadsorption-negative mutants of <i>Mycoplasma pneumoniae</i> ," <u>Infect. Immun.</u> 32:127-136 (1981).
59	Kahane et al., "Attachment of mycoplasmas to erythrocytes: a model to study mycoplasma attachment to the epithelium of the host respiratory tract," <u>Isr. J. Med. Sci.</u> 17:589-592 (1981).

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**  
*(Use several sheets if necessary)*

Applicant  
Higuchi et al.

Filing Date  
March 1, 2002

A circular stamp with "U.S. PATENT & TRADEMARK OFFICE" around the perimeter. The date "DEC 22 2003" is in the center, with "SEARCHED" at the top and "INDEXED" at the bottom.

## **Examiner**

### Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.